Scarica l'app Stockscreener
77.97
0.00%
0.00
Dopo l'orario di chiusura:
77.97
Precedente Chiudi:
$77.97
Aprire:
$78.36
Volume 24 ore:
107.62K
Relative Volume:
0.50
Capitalizzazione di mercato:
$523.35M
Reddito:
-
Utile/perdita netta:
$-14.99M
Rapporto P/E:
-37.73
EPS:
-2.0665
Flusso di cassa netto:
$-10.01M
1 W Prestazione:
-8.52%
1M Prestazione:
-32.95%
6M Prestazione:
+41.43%
1 anno Prestazione:
-19.79%
Intervallo 1D:
$77.03
$80.00
Intervallo di 1 settimana:
$77.03
$86.69
Portata 52W:
$50.07
$124.82
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
77.97 | 572.11M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Iniziato | Leerink Partners | Outperform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-09-09 | Iniziato | BTIG Research | Buy |
| 2025-09-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-08-26 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Form 144 MONOPAR THERAPEUTICS INC For: 1 October By Investing.com - Investing.com Canada
16,800 shares are proposed for sale by Monopar Therapeutics (MNPR) director Christopher Starr. - Stock Titan
Form 4 insider transaction filed pressures Monopar Therapeutics stock below $74.23 support - Traders Union
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Monopar Therapeutics CEO Robinson sells $2.5m in stock By Investing.com - Investing.com Canada
Four share sales at $87.15 to $89.79: Monopar Therapeutics (MNPR) CEO also exercised options. - Stock Titan
(MNPR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Monopar Therapeutics stock price prediction: Support pressure looms at $81.33 - Traders Union
Form 144 MONOPAR THERAPEUTICS INC. For: 25 September By Investing.com - Investing.com Nigeria
Stock-option shares are proposed for sale by Chandler Robinson at Monopar Therapeutics (NASDAQ: MNPR). - Stock Titan
Monopar Therapeutics stock falls 7.5 percent on September 23 - AD HOC NEWS
Monopar Therapeutics shares drop more than 7% after stock trades below short-term moving averages - Traders Union
Why is Monopar Therapeutics stock down today? Key support levels to watch - Traders Union
Monopar Therapeutics stock trades on a clinical pipeline catalyst - AD HOC NEWS
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Monopar Therapeutics Inc (1IY0.MU) Analyst insights, Price targets and RecommendationsYahoo Finance - Yahoo Finance Singapore
Monopar Therapeutics stock trades quietly as investors weigh recent trial and funding updates - AD HOC NEWS
Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to S&P Biotechnology Select Industry Index - marketscreener.com
MNPR slides nearly 5% as technical indicators confirm continued short-term weakness - Traders Union
Monopar Therapeutics stock trades near $92.46 support amid ongoing pullback - Traders Union
Monopar Therapeutics stock forecast: Selloff remains in focus - Traders Union
Monopar Therapeutics Is Maintained at Overweight by Barclays - Moomoo
MNPR Maintained by Barclays -- Price Target Raised to $145 - GuruFocus
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145 - Moomoo
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally - Traders Union
Monopar Therapeutics stock trades near record levels as investors react to insider selling and stron - AD HOC NEWS
What's behind Monopar Therapeutics's latest 3.0% stock pullback? - Traders Union
MNPR Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.62 Highlights Clinical-Stage DisciplineEPS Miss Report - dars.gov.et
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises - Stock Titan
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock By Investing.com - Investing.com Canada
Monopar (MNPR) insider sells at $110–113 after $30 option exercise - Stock Titan
Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling? - Traders Union
Monopar director Kim Tsuchimoto sells $455k in common stock By Investing.com - Investing.com Nigeria
Monopar Therapeutics director Raymond Anderson sells $351k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Director Kim R. Tsuchimoto Executes Six-Tranche Stock Sale Under Rule 10b5-1 Plan - Kalkine Media
Monopar Therapeutics (MNPR) CMO uses plan to exercise options - Stock Titan
Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares - Bitget
Monopar Therapeutics (MNPR) director sells 3,142 shares in plan trade - Stock Titan
Monopar Therapeutics (MNPR) director plans $906K share sale - Stock Titan
Monopar Therapeutics stock resistance test: Key levels to watch - tradersunion.com
Monopar (NASDAQ: MNPR) director to sell 6,284 shares - Stock Titan
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - webull.com
Monopar (MNPR) Quarter in Focus: EPS Clears the Reported Estimate in the Current Update; Trading Response: Shares Close 2.85% Lower in the Latest SessionForward EPS Estimate - vinanet.vn
Monopar (MNPR) Latest: Ends Lower by 2.85% at $107.72 in the Latest Reading; Technical Setup: Price Remains Between $102.33 Support and $113.11 Resistance at the CloseBreak of Structure - vinanet.vn
MNPR drops as short-term selling pressure persists - Traders Union
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130 - Moomoo
What's behind Monopar Therapeutics's latest stock pullback? - Traders Union
Monopar (MNPR) Chart: Retreats 2.41% to $120.85 in the Latest Reading; Price Levels: $114.81 and $126.89 Define the Nearby Reference Levels under the Current SnapshotLeveraged ETF Flow - vinanet.vn
Monopar (MNPR) Earnings Report: EPS Beats Its Estimate for the Current Session; Session Move: The Stock Ends Up 4.02% in the Latest ReadingInterim Report - vinanet.vn
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Monopar Therapeutics Inc Azioni (MNPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Robinson Chandler | Chief Executive Officer |
Sep 24 '26 |
Option Exercise |
21.74 |
29,056 |
631,680 |
128,323 |
| Robinson Chandler | Chief Executive Officer |
Sep 24 '26 |
Sale |
88.00 |
29,056 |
2,556,851 |
99,267 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):